Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top

International Journal of Clinical Oncology

Issue 9/2025 Including Invited Reviews on Progress in management of bone and soft tissue tumor

Content (22 Articles)

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma

Noriomi Matsumura, Masaki Mandai

Treatment strategies and prognosis of superficial laryngo-pharyngeal cancer: a literature review

  • Open Access
  • Metastasis
  • JSCO Board of Directors Series

Kazuchika Ohno, Takahiro Asakage

The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling

  • Open Access
  • JSCO Board of Directors Series

Junichi Matsubara, Kumi Mukai, Manabu Muto

Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function

Shunsaku Nakagawa, Keiko Ikuta, Takashi Masuda, Tomohiro Terada

A perspective on patient-derived orthotopic xenograft (PDOX) mouse models for identification of novel and individualized treatment for sarcoma

Takashi Higuchi, Kentaro Igarashi, Shinji Miwa, Hiroaki Kimura, Katsuhiro Hayashi, Satoru Demura, Sei Morinaga, Yohei Asano, Norio Yamamoto, Francis J. Hornicek, Hiroyuki Tsuchiya, Robert M. Hoffman

Advances in liquid biopsy for bone and soft-tissue sarcomas

  • Open Access
  • Sarcoma
  • Invited Review Article

Yilang Wang, Tomohiro Fujiwara, Takanao Kurozumi, Teruhiko Ando, Takahiko Ishimaru, Hiroya Kondo, Eiji Nakata, Toshiyuki Kunisada, Toshifumi Ozaki

Current and emerging systemic treatment options for malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Satoru Demura

Association between increased proteinuria induced by Bevacizumab, Ramucirumab, and Aflibercept and the risk of renal impairment and failure: a systematic review and meta-analysis

Yuma Shibutani, Maki Nishizaki

Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study

Keisuke Okamoto, Yoshitaka Saito, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Katsuya Narumi, Mitsuru Sugawara, Masaki Kobayashi

Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer

Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Kunihiro Fushiki, Kotoe Oshima, Akihiro Ohba, Takeshi Kawakami, Takahiro Tsushima, Hirofumi Yasui, Kentaro Yamazaki, Yusuke Onozawa, Takashi Mukaigawa, Yasuhiro Tsubosa, Hirofumi Ogawa, Tsuyoshi Onoe

Pterygomandibular raphe invasion as a novel grading and prognostic factor for squamous cell carcinoma of buccal mucosa: a retrospective study with propensity score matching

  • Open Access
  • Original Article

Ryoji Yoshida, Riu Lin, Keisuke Yamana, Takeshi Obayashi, Hisashi Takeshita, Kosuke Shinohara, Kenta Kawahara, Masatoshi Hirayama, Nozomu Takahashi, Akiyuki Hirosue, Masanori Shinohara, Hideki Nakayama

Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

Nobuaki Mamesaya, Keita Mori, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi

Different outcomes by sex in metastatic gastrointestinal stromal tumor patients receiving imatinib: a trial-level analysis

Antonella Venturino, Giuseppe Antonio Colloca

Characteristics of gut microbiota in high-methylated colorectal cancer

Tatsushi Saito, Hideaki Karasawa, Kota Ouchi, Tomoyuki Ono, Taiki Kajiwara, Atsushi Kohyama, Wakako Ikeda-Ohtsubo, Shinji Fukuda, Fumiyoshi Fujishima, Yohei Ozawa, Hideyuki Suzuki, Kazuhiro Watanabe, Chikashi Ishioka, Takashi Kamei, Shinobu Ohnuma, Takaaki Abe, Michiaki Unno

The Metazoan SpoT Homolog 1 promotes ferroptosis by regulating the intracellular redox cycle and iron levels in hepatocellular carcinoma

Yuki Nakayama, Shinji Itoh, Takeo Toshima, Kyohei Yugawa, Shohei Yoshiya, Norifumi Iseda, Yuriko Tsutsui, Katsuya Toshida, Takuma Ishikawa, Tomoharu Yoshizumi

Clinical utility of a novel perioperative quality assessment metric, trifecta, for radical cystectomy

Mahito Atsuta, Fumihiko Urabe, Kosuke Iwatani, Masataka Kubo, Naoki Uchida, Hirokazu Kagawa, Naoya Tomomasa, Shun Saito, Takayuki Sano, Wataru Fukuokaya, Kazuhiro Takahashi, Takafumi Yanagisawa, Shunsuke Tsuzuki, Takahiro Kimura, Jun Miki

Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study

Daiki Ikarashi, Nozomi Hayakawa, Go Kaneko, Yuma Sakura, Yuki Endo, Ryo Yamashita, Suguru Shirotake, Yukihiro Kondo, Eiji Kikuchi, Wataru Obara

Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients

Taisuke Tobe, Jun Teishima, Hideto Ueki, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Koji Chiba, Akihisa Yao, Hideaki Miyake

Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study

Fumiya Yoneyama, Naoki Fujita, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Ryuma Tanaka, Takuya Oishi, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama

Outcomes of cases with complete hydatidiform mole coexisting with a fetus: a single-center study

Kaoru Niimi, Mayu Shibata, Kosuke Yoshida, Eiko Yamamoto, Seiji Sumigama, Yuko Yasui, Yuki Nishiko, Kimihiro Nishino, Hiroaki Kajiyama

Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis

Laura Vertechy, Raffaella Ergasti, Cristina Chiamenti, Davide Arrigo, Ilary Ruscito, Alessandra Rizzi, Serena Maria Boccia, Carolina Maria Sassu, Giovanni Scambia, Anna Fagotti, Claudia Marchetti

Correction to: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study

Yasuhiro Fujisawa, Shusuke Yoshikawa, Tatsuya Takenouchi, Shoichiro Mori, Jun Asai, Hisashi Uhara, Yuki Ichigosaki, Taku Fujimura, Yoshiyuki Nakamura, Yasuhiro Nakamura, Fumitaka Ohno, Takeshi Fukumoto, Toshiyuki Ozawa, Kenjiro Namikawa, Satoru Sugihara, Toshihiko Hoashi, Takatoshi Shimauchi, Yu Sawada, Hiroaki Iwata, Taku Maeda, Takuya Miyagawa, Yoshitsugu Shibayama, Naohito Hatta, Akiko Kishi, Masashi Ishikawa, Hisao Kawahira, Norito Katoh, Ryuhei Okuyama

Aug 25
Issue: 8/2025
Including Invited Reviews on Current status and perspective for palliative radiotherapy
Oct 25
Issue: 10/2025
Including Invited Reviews on Significance of BRCA genetic test for breast cancer

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Case simulations: Biomarker-driven management of NSCLC (Link opens in a new window)

Do you want to assess your biomarker testing skills and management decisions? Use these simulation-based case studies based on realistic NSCLC scenarios to do so in a practical and secure environment.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
COMMISSIONED

How-to guide for healthcare professionals: understanding genomic reports

This educational activity was initiated, funded and co-developed by Boehringer Ingelheim and is intended for healthcare professionals in the UK and Ireland only. 

Genomic testing helps inform cancer diagnosis, prognosis, and treatment. A genomic report is generated by the laboratory carrying out next-generation sequencing to analyze biopsy samples. Access this educational microsite to learn more about typical genomic report content and how to interpret test results for patients with cancer.

NP-GB-106631 | Jan 2026

Commissioned by:
  • Boehringer Ingelheim
Learn more
Image Credits
Biomarker-driven management of NSCLC logo/© Springer Health+ IME, DNA double helix structure on a purple background/© 2025 Adobe